Nov. 12 (Bloomberg) -- Actavis is said to be in talks with Allergan on a acquisition that could be worth more than $60 billion. Bloomberg’s Erik Schatzker and Stephane Ruhle examine the potential deal and look at the numerous activist investors involved on both sides. They speak on “Market Makers.”